Join Adelaide Capital for Microbix’s Q1 Earnings Webinar!

TSX: MBX OTCQX: MBXBF

Microbix Biosystems creates proprietary biological products for human health, with over 120 skilled employees and revenues now targeting C$ 2.0 million or more per month. It enables the worldwide commercialization of diagnostic assays by making a wide range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs™) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its antigens drive the antibody tests of approximately 100 diagnostics makers, while QAPs are sold to clinical lab accreditation organizations, diagnostics companies, and clinical labs. Microbix QAPs are now available in over 30 countries, supported by a network of international distributors. Microbix is ISO 9001 & 13485 accredited, U.S. FDA registered, Australian TGA registered, Health Canada establishment licensed, and provides IVDR-compliant CE marked products.

Microbix also applies its biological expertise and infrastructure to develop other proprietary products and technologies, most notably Kinlytic® urokinase, a biologic thrombolytic drug used to treat blood clots, and reagents or media to support molecular diagnostic testing (e.g., its DxTM™ for patient-sample collection). Microbix is traded on the TSX and OTCQX, and headquartered in Mississauga, Ontario, Canada.

Join Adelaide Capital for a webinar featuring Horizon Petroleum!

Horizon (TSXV: HPL) is a European-focused development company that boasts a management team with worldwide experience, including Poland, with a track record of reserve, production, and corporate growth. Horizon plans to acquire additional conventional natural gas and oil assets in Europe to take advantage of the high natural gas prices and large natural gas requirements for the region.

The Company recently acquired 100% interest in a conventional natural gas development asset in Poland containing 189Bcfe of 2P reserves plus 2C Risked Contingent Resources with a before-tax NPV10 of USD$460MM in the core area with significant development upside. The initial work program will provide cash flow in 2025. Acquisition costs $1.08MM, C$1MM shares in Horizon, and a profit share of 6%. The first cash flow is expected in 2025 with exponential production growth from currently zero to 30mmcf/day by 2027 and growth expected to continue until 2029.

Horizon is constantly evaluating new development assets in stable, investment-friendly jurisdictions. Europe’s energy needs are growing as Russian gas cut-offs have pushed many countries into states of emergency already this winter. Natural gas will also assist many countries that still rely on coal to transition to a cleaner form of energy for power generation.

Join Adelaide Capital for Microbix’s Q4 and Year-End Earnings Webinar!

TSX: MBX OTCQX: MBXBF

Microbix Biosystems Inc. creates proprietary biological products for human health, with over 100 skilled employees and sales now targeting C$ 2.0 million monthly.

Microbix makes and exports a wide range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs™) that support clinical lab proficiency testing, enable assay development and validation or help ensure the quality of clinical diagnostic workflows. Its antigens drive the antibody tests of approximately 100 diagnostics makers, while QAPs are sold to clinical lab accreditation organizations, diagnostics companies, and clinical labs. Microbix QAPs are now available in over 30 countries, supported by a network of international distributors. Microbix is ISO 9001 & 13485 accredited, U.S. FDA registered, Australian TGA registered, Health Canada establishment licensed, and provides CE-marked products.

Microbix also applies its biological expertise and infrastructure to develop other proprietary products and technologies, most notably Kinlytic® urokinase, a biologic thrombolytic drug used to treat blood clots, and reagents or media to support molecular diagnostic testing (e.g., its DxTM™ for patient-sample collection).

Microbix is traded on the TSX and OTCQX and is headquartered in Mississauga, Ontario, Canada.

Subscribe to Adelaide Capital’s YouTube channel to catch all webinar replays!

Join Adelaide Capital for iFabric (TSX: IFA, OTCQX: IFABF) Investor Webinar

Headquartered in Markham, Ontario, iFabric, www.ifabriccorp.com, is listed on the TSX and, currently has 30.3 million shares issued and outstanding. Its two strategic divisions offer a variety of products and services through wholly-owned subsidiaries, namely, Intelligent Fabric Technologies (North America) Inc. ("IFTNA") and Coconut Grove Pads Inc. ("Coconut Grove"). IFTNA is focused on development and sale of high-performance sports apparel, medical protective apparel, consumer protective apparel, and proprietary treatments that provide “intelligent” properties to fabrics, foams, plastics, and numerous other surfaces, thereby improving the safety and well-being of the user. Such intelligent properties include antiviral and antibacterial characteristics, water-repellence and UV protection, among others. Coconut Grove, operating as Coconut Grove Intimates, is a designer, manufacturer, distributor, licensor and licensee of ladies’ intimate apparel products and accessories.

Join Adelaide Capital for Intro to Microbix (TSX: MBX, OTCQX: MBXBF) Investor Webinar

This webinar is designed for investors new or newish to Microbix. Cameron Groome, CEO, will walk us through the story and explain the different business divisions and products. There will be a Q&A at the end of the session. Microbix Biosystems Inc. creates proprietary biological products for human health, with over 100 skilled employees and sales now targeting C$ 2.0 million per month. It makes and exports a wide range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs™) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its antigens drive the antibody tests of approximately 100 diagnostics makers, while QAPs are sold to clinical lab accreditation organizations, diagnostics companies, and clinical labs. Microbix QAPs are now available in over 30 countries, supported by a network of international distributors. Microbix is ISO 9001 & 13485 accredited, U.S. FDA registered, Australian TGA registered, Health Canada establishment licensed, and provides CE marked products. Microbix also applies its biological expertise and infrastructure to develop other proprietary products and technologies, most notably Kinlytic® urokinase, a biologic thrombolytic drug used to treat blood clots, and reagents or media to support molecular diagnostic testing (e.g., its DxTM™ for patient-sample collection). Microbix is traded on the TSX and OTCQX, and headquartered in Mississauga, Ontario, Canada.

Join Adelaide Capital for Tantalus Investor Update Webinar

Tantalus (TSX: GRID) is a technology company dedicated to helping utilities modernize their distribution grids by harnessing the power of data across all their devices and systems deployed throughout the entire distribution grid. We offer a grid modernization platform across multiple levels: intelligent connected devices, communications networks, data management, enterprise applications and analytics. Our solutions provide utilities with the flexibility they need to get the most value from existing infrastructure investments while leveraging advanced capabilities to plan for future requirements. Learn more at http://www.tantalus.com/.

Join Adelaide Capital for Journey Energy’s Q3 & Operational Update Webinar!

Join us for Surge Energy’s Investor Update Webinar, where we will provide key insights into the their recent news.

Surge Energy (TSX: SGY) is a leading oil-focused exploration and production (E&P) company, producing 24,000 boepd, 87% levered to oil. Surge operates in two of the most economical plays in North America: the Sparky and SE Saskatchewan, offering significant drilling inventory.

Surge strategically targets low-risk, high-quality conventional reservoirs and boasts over 2.5 billion barrels of net original oil in place (OOIP) with an 8.7% cumulative recovery factor to date. The Company’s yearly dividend of $0.52/share is paid monthly, and they also have an NCIB. They currently trade close to their PDP value of $5.69, at a steep discount to their 1P value of $10.86 and 2P value of $16.72, with a free cash flow yield of 10%.

Surge trades on the TSX under the symbol SGY. For more information, visit www.surgeenergy.ca.

Join us for Mako Mining’s Investor Update Webinar, where we will provide key insights into the company's recent news.

Mako Mining is a publicly listed gold mining, development and exploration company. The Company operates the high-grade San Albino gold mine in Nueva Segovia, Nicaragua, which ranks as one of the highest-grade open pit gold mines globally.

Mako's primary objective is to operate San Albino profitably and fund exploration of prospective targets on its district-scale land package. The Company also owns 100% of the gold project Eagle Mountain in Guyana, South America.

We will discuss Mako's latest Q3 2024 operational results for the San Albino Mine, along with providing an update on the Eagle Mountain Gold Project.

The session will conclude with a live Q&A, offering participants the opportunity to ask questions and engage directly with the Mako team.

Mako trades on the TSXV under the symbol MKO and on the OTCQX under the symbol MAKOF . For more information, visit www.makominingcorp.com.

Join us for Talisker Resources' Investor Update Webinar, where we will provide key insights into the company's recent news.

Talisker Resources is a junior resource company involved in the exploration and development of gold projects in British Columbia, Canada.

We will discuss the latest updates of its flagship Bralorne Gold Project, where the company has made significant progress over the past five years, including 165,000 meters of drilling and the discovery of over 50 additional veins.

Talisker also recently announced a $21.5 million financing package. These funds will be used to advance the Bralorne Gold Project and support general corporate activities. As Talisker transitions from exploration to mining, with gold prices at record highs, the company is well-positioned to become one of Western Canada’s next gold producers.

The session will conclude with a live Q&A, offering participants the opportunity to ask questions and engage directly with the Talisker team.

Talisker trades on the TSX under the symbol TSK and on the OTCQX under the symbol TSKFF. For more information, visit www.taliskerresources.com

Join us for TriStar Gold's Investor Update Webinar, where we will provide key insights into the company's recent news.

TriStar Gold is an exploration and development company focused on precious metals properties in the Americas, with the potential to become significant producing mines.

We will discuss the latest updates on its flagship Castelo de Sonhos gold project in Pará State, Brazil, including the recently announced statement on requests related to Castelo de Sonhos. The session will conclude with a live Q&A, offering participants the opportunity to ask questions and engage directly with the TriStar team.

TriStar Gold trades on the TSX Venture Exchange under the symbol TSG and on the OTCQB under the symbol TSGZF. For more information, visit www.tristargold.com

Nu E Power Corporation - NUE: CSE

• Current Market Cap $18.1M

• Shares O/S 30.50M

• Warrants 7.425M @ $0.50

• Options 2.1M @$0.50

• FD Shares O/S 40.13

Mandate: To develop and construct renewable energy infrastructure across North America focusing on solar in Alberta.

Management has previous extensive experience in this field and has 600 MW under various stages of development in Alberta with the plan to increase to 2GW.

Why Alberta:

• Abundant solar resources

• Shift away from coal is almost complete.

• Deregulated electricity market

• Federal Clean Energy programs and incentives

• which will refund 30% of cost of investment

• Recipient of carbon credits

Nu E Advantage:

• Unlike many renewable energy companies, NU E has a financial partnership with Low Carbon out of the UK (49% owned by Mass Mutual) and has committed to funding up to $1.5 billion by mid-2027 in renewable infrastructure. Low Carbon currently has >30GW of projects globally, in different phases of construction.

• NU E is responsible for project generation and permitting. Will receive an FID bonus and 25% of Revenue after the projects reach payout and cover 50% of G&A during this process. NU E has the option to hold or sell any of these projects

• Free cash flow of $10.9M expected in next 24 months.

Projects:

• 8.75MW solar development in Lethbridge AB with first production slated for Q3 2024

• Four other projects totalling 495.5 MW in various stages of permitting

Green Hydrogen:

• NU E just announced the acquisition of $49% of Diloo Energy Corporation for $4M (the share exchange ratio will be determined upon signing of the definitive agreement. Diloo is partnered with numerous Indigenous groups and is developing 120MW of clean energy in Alberta by permitting and constructing green hydrogen Infrastructure.

• Devon Sandford (Founder) has broad experience on multiple levels in project development and will be the incoming CEO, upon closing.